CRISPR Therapeutics CFO sells 29,700 shares

Accepted by SEC EDGAR 01/08/2026 - 05:35 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

CRISPR Therapeutics AG Chief Financial Officer Prasad Raju exercised stock options for 29,700 Common Shares on January 6, 2026 at exercise prices of $45.15 and $44.31 per share, then sold 29,700 Common Shares at weighted average prices of $60.1799, $60.0000 and $60.2134 per share under a Rule 10b5-1 trading plan adopted on August 18, 2025. Following these transactions, he directly holds 84,132 stock options and 6,767 Common Shares.

Insider Trade Summary

Exercise and Sale: 29,700 shares ($451K approx. pre-tax spread)

Exercise and Sale 7 txns

Insider Prasad Raju

Role Chief Financial Officer

Sold 29,700 shs ($1.79M)

Approx. gross sale proceeds $1.79M

Approx. exercise cost $1.34M

Approx. pre-tax spread $451K

Share of Position Sold 81.4%

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	23,361	$0.00	$0.00
Exercise	Stock Option (Right to Buy)	6,339	$0.00	$0.00
Exercise	Common Shares	23,361	$45.15	$1.05M
Exercise	Common Shares	6,339	$44.31	$281K
Sale	Common Shares	18,933	$60.1799	$1.14M
Sale	Common Shares	5,004	$60.00	$300K
Sale	Common Shares	5,763	$60.2134	$347K

Holdings After Transaction: Stock Option (Right to Buy) — 84,132 contracts (Direct); Common Shares — 6,767 shares (Direct)

Holdings Before and After: Stock Option (Right to Buy), 113,832 to 84,132 contracts (Direct); Common Shares, 6,767 to 6,767 shares (Direct)

Footnotes (5)

1. F1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.0000 to $60.7300, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
3. F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.0000 to $60.4800, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
4. F4. This option was granted on March 14, 2023 with respect to 100,000 Common Shares, with 25% of the shares vesting on March 14, 2024 and the remaining shares vesting on each monthly anniversary thereafter for a period of 36 months.
5. F5. This option was granted on October 13, 2023 with respect to 13,832 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 13, 2023.

Key Figures

Shares sold: 29,700 shares Shares acquired via option exercise: 29,700 shares Option exercise price: $45.1500 per share +4 more

7 metrics

Shares sold 29,700 shares Total Common Shares sold on January 6, 2026

Shares acquired via option exercise 29,700 shares Total Common Shares from exercised stock options on January 6, 2026

Option exercise price $45.1500 per share Exercise price for 23,361 options expiring March 14, 2033

Option exercise price $44.3100 per share Exercise price for 6,339 options expiring October 13, 2033

Post-transaction stock options held 84,132 options Direct stock options held after the reported transactions

Post-transaction Common Shares held 6,767 shares Direct Common Shares held after the reported transactions

Rule 10b5-1 plan adoption date August 18, 2025 Trading plan governing the reported sales

Key Terms

Rule 10b5-1 trading plan, weighted average price, Stock Option (Right to Buy), vest in 48 equal monthly installments

4 terms

Rule 10b5-1 trading plan regulatory

"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

vest in 48 equal monthly installments financial

"100% of the shares will vest in 48 equal monthly installments"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did CRSP CFO Prasad Raju report in this Form 4?

CFO Prasad Raju reported exercising stock options for 29,700 Common Shares on January 6, 2026 at exercise prices of $45.15 and $44.31 per share, then selling 29,700 Common Shares at weighted average prices of $60.1799, $60.0000 and $60.2134 per share.

How many CRSP shares and options does Prasad Raju hold after these transactions?

After the reported transactions, Prasad Raju directly holds 6,767 Common Shares of CRISPR Therapeutics and 84,132 stock options. These figures reflect his post-transaction positions as reported in the canonical holdings data associated with this Form 4 filing.

Were the CRSP share sales by CFO Prasad Raju under a Rule 10b5-1 plan?

Yes. The sales were effected under a Rule 10b5-1 trading plan adopted by Prasad Raju on August 18, 2025. Such plans pre-arrange trades, providing a structured framework for selling shares over time according to preset instructions.

What stock option grants did Prasad Raju exercise in this CRSP Form 4?

He exercised stock options covering 23,361 Common Shares granted on March 14, 2023 at an exercise price of $45.15 per share and 6,339 Common Shares granted on October 13, 2023 at an exercise price of $44.31 per share, totaling 29,700 shares.

On what date did the CRSP CFO’s reported transactions occur and what was the net share effect?

All reported exercises and sales occurred on January 6, 2026. He exercised options for 29,700 shares and sold 29,700 shares, resulting in a net sell of 29,700 in terms of buy-sell activity, as summarized in the transaction data.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Prasad Raju

(Last) (First) (Middle)

C/O CRISPR THERAPEUTICS

105 WEST FIRST STREET

(Street)

BOSTON MA 02127

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CRISPR Therapeutics AG [ CRSP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	01/06/2026		M		23,361	A	$45.15	30,128	D
Common Shares	01/06/2026		M		6,339	A	$44.31	36,467	D
Common Shares	01/06/2026		S(1)		18,933	D	$60.1799(2)	17,534	D
Common Shares	01/06/2026		S(1)		5,004	D	$60	12,530	D
Common Shares	01/06/2026		S(1)		5,763	D	$60.2134(3)	6,767	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$45.15	01/06/2026		M			23,361	(4)	03/14/2033	Common Shares	23,361	$0.00	76,639	D
Stock Option (Right to Buy)	$44.31	01/06/2026		M			6,339	(5)	10/13/2033	Common Shares	6,339	$0.00	7,493	D

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.0000 to $60.7300, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.0000 to $60.4800, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

4. This option was granted on March 14, 2023 with respect to 100,000 Common Shares, with 25% of the shares vesting on March 14, 2024 and the remaining shares vesting on each monthly anniversary thereafter for a period of 36 months.

5. This option was granted on October 13, 2023 with respect to 13,832 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 13, 2023.

	/s/ Elizabeth Ryland Waldinger, attorney-in-fact	01/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.